ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Fate Therapeutics Inc

Fate Therapeutics Inc (FATE)

4.54
0.27
(6.32%)
Closed July 22 4:00PM
4.56
0.00
( 0.00% )
Pre Market: 4:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.56
Bid
3.86
Ask
5.00
Volume
-
0.00 Day's Range 0.00
1.63 52 Week Range 8.83
Market Cap
Previous Close
4.56
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
2,336,874
Shares Outstanding
113,831,969
Dividend Yield
-
PE Ratio
-3.23
Earnings Per Share (EPS)
-1.41
Revenue
63.53M
Net Profit
-160.93M

About Fate Therapeutics Inc

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, includ... Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Fate Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker FATE. The last closing price for Fate Therapeutics was $4.56. Over the last year, Fate Therapeutics shares have traded in a share price range of $ 1.63 to $ 8.83.

Fate Therapeutics currently has 113,831,969 shares outstanding. The market capitalization of Fate Therapeutics is $519.07 million. Fate Therapeutics has a price to earnings ratio (PE ratio) of -3.23.

FATE Latest News

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.6817.52577319593.8853.8832298104.4754016CS
40.7319.06005221933.8353.02518682303.90980285CS
120.5914.86146095723.9753.02523368743.84595449CS
26-0.24-54.88.833.02525918895.35176975CS
520.061.333333333334.58.831.6323656764.21402162CS
156-81.11-94.677249912585.6797.431.63201070415.16794316CS
260-17.93-79.724321920922.49121.161.63158829723.54045138CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NMHINatures Miracle Holding Inc
$ 0.9935
(183.86%)
5.41M
GPGreenPower Motor Company Inc
$ 1.79
(59.11%)
4
FEIMFrequency Electronics Inc
$ 13.30
(31.68%)
40.96k
LGHLWLion Group Holding Ltd
$ 0.0093
(30.99%)
156
ENGENGlobal Corp
$ 2.22
(29.82%)
258
RNAZTransCode Therapeutics Inc
$ 0.3395
(-57.16%)
263.82k
MIRAMIRA Pharmaceuticals Inc
$ 3.69
(-26.35%)
659.83k
NUKKNukkleus Inc
$ 0.3892
(-21.85%)
116.87k
CMAXCareMax Inc
$ 4.08
(-21.39%)
159.5k
XCURExicure Inc
$ 0.4119
(-17.59%)
5.36k
NMHINatures Miracle Holding Inc
$ 0.9935
(183.86%)
5.41M
LIFWMSP Recovery Inc
$ 0.6287
(24.08%)
2.68M
BREABrera Holdings PLC
$ 0.6661
(-9.63%)
1.53M
SLNASelina Hospitality PLC
$ 0.0347
(-6.22%)
964.09k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 14.41
(0.84%)
795.85k

FATE Discussion

View Posts
NY1972 NY1972 1 week ago
CART or CARNK need ICEs to engage endogenous NK and macrophages to combat MRD.
πŸ‘οΈ0
jondoeuk jondoeuk 2 weeks ago
The study showed that blocking TGF-B signalling is necessary for the effective treatment of hepatocellular carcinoma (and likely other solid tumours that have high TGF-B levels) with iPSC-derived NK cells https://www.cell.com/cell-stem-cell/abstract/S1934-5909(24)00217-0

πŸ‘οΈ0
Monksdream Monksdream 3 weeks ago
FATE under $5
πŸ‘οΈ0
harry crumb harry crumb 3 weeks ago
Will it short down to the 2.50 area again, time will tell
πŸ‘οΈ0
jondoeuk jondoeuk 4 weeks ago
They will use the standard flu/cy as part of the conditioning regime, but also either cyclophosphamide or bendamustine. They have been testing the integration of the ADR tech in next-gen iPSC-derived CD8+ CAR T-cells, which could allow conditioning-free therapy. Adding additional edits could prevent rejection as well https://www.biorxiv.org/content/10.1101/2023.10.09.557143v1.full
πŸ‘οΈ0
NY1972 NY1972 1 month ago
Make sense. 100% depletion of B cells probably not ideal outcome anyway.
πŸ‘οΈ0
jondoeuk jondoeuk 1 month ago
In the second half, they expect to read-out initial PhI data for the first 3-5 patients treated with FT819 for moderate to severe SLE. They seek to administer FT819 without fludarabine and instead with commonly used treatment regimens for autoimmune diseases. They seek to demonstrate the potential of the proprietary ADR tech. Specifically, they expect to read-out 3-5 patients treated with FT522 in the PhI for B-cell lymphoma. They seek to broadly investigate FT522 without conditioning chemo for treatment of various B-cell autoimmune diseases. They seek to establish an initial clinical proof-of-concept with the first 3-5 patients treated with FT825 in the PhI for advanced solid tumours. Also, plan to disclose new target(s) and product configurations for at least two next-gen product candidates.
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
The CEO should follow (or be kicked) given his poor communication and disastrous performance https://ir.fatetherapeutics.com/node/13526/html
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
Shinobi Therapeutics and Anocca will co-develop allogeneic T-cell receptor engineered induced pluripotent stem cells (TCR-iPs-Ts) for solid tumors https://www.bioprocessintl.com/deal-making/shinobi-and-anocca-to-advance-cancer-killing-ips-t-cell-therapies
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
"T cell engagers did not appear to drive deep/durable remissions beyond treatment and as such would require chronic therapy,'' Dr. Schett*

*Cantor Fitzgerald research note April 29, 2024.
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
First Quarter Financial Results and Business Updates https://www.marketscreener.com/quote/stock/FATE-THERAPEUTICS-INC-14297698/news/Fate-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Business-Updates-46682981/
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program https://www.globenewswire.com/news-release/2024/05/09/2878757/24675/en/Fate-Therapeutics-Announces-First-Lupus-Patient-Treated-in-Phase-1-Autoimmunity-Study-of-Off-the-shelf-FT819-CAR-T-cell-Program.html
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
LBA https://www.globenewswire.com/fr/news-release/2024/05/03/2875365/24675/en/Fate-Therapeutics-Announces-Presentation-of-FT522-Preclinical-Data-for-Autoimmune-Diseases-in-Late-breaking-Abstract-at-ASGCT-Annual-Meeting.html
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
Novel a3-MICA/B-specific CAR T-cell immunotherapy demonstrates ubiquitous targeting of cancer cells and resistance to immune-surveillance evasion https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=59250

FT819-102: Clinical Translation of Off-the-Shelf TCR-Less CD8ab+ Anti-CD19 CAR-T Cells for the Treatment of B Cell-Mediated Autoimmune Disorders https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=60404
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
Depends if the companies are holding on to autoimmune diseases as their last straw. If so, it could be the end of them.
👍️ 1
NY1972 NY1972 3 months ago
What is CARNK bios going to do if T cell engagers eat the autoimmune pie?
πŸ‘οΈ0
jondoeuk jondoeuk 3 months ago
A case report https://www.ejcancer.com/article/S0959-8049(24)00727-5/fulltext
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
FATE under $5
πŸ‘οΈ0
harry crumb harry crumb 3 months ago
Entry at 3.50’s coming again
πŸ‘οΈ0
jondoeuk jondoeuk 3 months ago
Found this https://www.nature.com/articles/s41591-024-02964-1

They used two cycles of low-dose blinatumomab in refractory rheumatoid arthritis (N=6). There was robust B-cell depletion with a 50% reduction in relevant auto-antibodies. Some minor fevers. However, most patients were then put on maintenance abatacept, so little insight into durability.
πŸ‘οΈ0
harry crumb harry crumb 3 months ago
4 area is loading zone again, over an over my friends
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
(OT) Shinobi announced their $51M Series A funding https://www.prnewswire.com/news-releases/shinobi-therapeutics-launches-with-completion-of-51m-series-a-to-advance-hypoimmune-ips-t-cell-therapy-platform-302012188.html

Targeting tech https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(23)00148-1

Immune evasion tech https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(23)00365-X
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
From last year https://finance.yahoo.com/news/cellorigin-announced-treatment-first-patient-170000142.html
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
DNA has acquired Modulus Therapeutics' cell therapy platform assets, including their CAR and switch receptor libraries https://www.prnewswire.com/news-releases/ginkgo-bioworks-acquires-modulus-therapeutics-cell-therapy-assets-to-strengthen-next-gen-car-designs-302105056.html
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
From this paper https://www.nature.com/articles/s41540-024-00355-3




Adoptive T-cell therapy also benefits from the combined activity of CD4+ and CD8+ T-cells, but FT819 is a CD8+ only T-cell therapy https://www.nature.com/articles/s41417-020-0183-x https://www.sciencedirect.com/science/article/pii/S0952791521001230 https://www.sciencedirect.com/science/article/pii/S0304419X2030158X https://www.science.org/doi/10.1126/science.1251102 https://www.nejm.org/doi/10.1056/NEJMoa0800251 https://www.science.org/doi/full/10.1126/sciadv.abe3348 https://www.science.org/doi/full/10.1126/sciadv.aba7443
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
1338 / 21 - Novel activation domains coupled to chimeric ILT receptors (CIR) enhance NK cell targeting of HLA-G+leukemic and solid tumor cells https://www.abstractsonline.com/pp8/#!/20272/presentation/6031
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
AACR abstracts

3618 / 24 - High-avidity BCMA CAR and high-affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma https://www.abstractsonline.com/pp8/#!/20272/presentation/7153

3995 / 4 - A novel chimeric Fas signal redirect receptor enhances the durability of anti-tumor activity and serial killing potential of CAR T cells https://www.abstractsonline.com/pp8/#!/20272/presentation/6132

5240 / 15 - Novel CD3-Fusion Receptor enables combination of T-cell engagers and allogeneic CAR T cells to promote enhanced antitumor activity and overcome antigen escape https://www.abstractsonline.com/pp8/#!/20272/presentation/6056
πŸ‘οΈ0
jondoeuk jondoeuk 4 months ago
Not many are in development. I know the PI of the trial in Germany said one of the chemo drugs used for lymphodepletion is (likely) playing a role as well.
πŸ‘οΈ0
harry crumb harry crumb 5 months ago
Fate always makes money again $$$$
πŸ‘οΈ0
NY1972 NY1972 5 months ago
No place to hide for many CARNK, CART bios

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1335998/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FIMMU_XXXXXXXX_auto-dlvrit
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
FATE new 52 week high
πŸ‘οΈ0
NY1972 NY1972 5 months ago
ACTs are turning into migrants armed with a pistol and name looking for a felon. They don't know the hoods and the local sheriffs. How long can they last in the hostile ground?
πŸ‘οΈ0
jondoeuk jondoeuk 5 months ago
Far more are going under quietly and unnoticed https://www.fiercebiotech.com/biotech/catamaran-sends-out-life-raft-financing-challenges-claim-another-biotech
πŸ‘οΈ0
jb128 jb128 5 months ago
Got back in a few months ago. Can we see another run to $120 like back in 2020-21 please??
πŸ‘οΈ0
harry crumb harry crumb 5 months ago
Very nice run to 6 again
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
(OT) Artec Biotech is built upon methods for differentiating iPSCs into NK cells, as well as proprietary modifications. One example is the alteration of checkpoint receptors, such as PD-1 KO, which will be used for ART-002. The lead is ART-001, an unmodified NK product.

Although iPSC-NKs and PB-NKs of the same donor exhibited similar gene expression profiles, analysis revealed notable differences in genes that are important for NK cell function. Some of these genes were highlighted. Given the success of checkpoint inhibition in treating certain types of cancer, they evaluated checkpoint receptor expression in iPSC-NKs compared to PB-NKs. As demonstrated by a recent study, the expression of multiple checkpoint inhibitors was significantly higher in CD73+ cells, and the frequency of CD73+ cells correlated with larger tumour size in breast cancer patients https://www.jci.org/articles/view/128895

In their differentiation system, they produced NKs with down-regulated CD73 expression.

The next gene of interest was PTGER4, which encodes prostaglandin E2 receptor 4 (EP4). In NK cells, the binding of prostaglandin E2 to the receptor can initiate immunosuppression. In contrast, EP4 inhibition has been shown to enhance NK antitumour activity https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1896643

EP4 was down-regulated.

TIGIT was another gene of focus. Although not expressed in iPSC-NKs, it was highly expressed in PB-NK control. Overall, TIGIT is variably expressed in human NKs. Notably, NKs with lower TIGIT expression have exhibited higher cytokine secretion capability, degranulation activity, and cytotoxic potential https://onlinelibrary.wiley.com/doi/10.1002/eji.201545480

Furthermore, blocking TIGIT expression via monoclonal antibodies alleviated NK exhaustion https://www.nature.com/articles/s41590-018-0132-0

Similar to TIGIT, cytokine-inducible Src homology 2–containing protein (CIS), encoded by the CISH gene, is also involved in cytokine secretion. CIS is a member of the suppressor-of-cytokine signaling family of proteins. CISH deletion in either iPSC-NKs or PB-NKs increases their sensitivity to IL-15 and enhances JAK/STAT and mTORC1 signaling. This leads to increased NK metabolic fitness that contributes to an improved antitumour response https://ashpublications.org/blood/article/137/5/624/463715/Targeting-a-cytokine-checkpoint-enhances-the

Their iPSC-NKs have significantly down-regulated CISH expression compared to PB-NKs.

Aside from direct mechanisms that tumours employ to down-regulate NK function, the tumour microenvironment also impairs NK function by negatively affecting NK metabolism https://www.frontiersin.org/articles/10.3389/fimmu.2019.02278/full

Enhancing NK metabolic functionality is currently being pursued as one of the avenues for increasing NK cell activity against tumours https://www.pnas.org/doi/10.1073/pnas.2107507118

Considering this, they further evaluated the metabolic profile of iPSC-NKs and PB-NKs. The assessment focused on significantly expressed genes, which impact NK metabolic function. The following genes showed up-regulation in iPSC-NKs: Slc2a1 (involved in glucose transport), Slc7a5 (an amino acid transporter), Slc3a2/CD98 (an amino acid transporter), and TFRC/CD71 (involved in receptor-mediated iron uptake). These data yield insight into the efficacy of iPSC-NKs because nutrient transport is essential and increased expression of nutrient transporters promotes an increased metabolic rate, as well as elevated NK activity https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02377-8
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
From last year (presented at SITC) https://jitc.bmj.com/content/11/Suppl_2/A1763
πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
(OT) oNKo-innate is a discovery-stage biotech company dedicated to target identification and preclinical IO (drug) development.

In this, the functional genomics and target discovery team have used their platform to perform enrichment screens in primary human NK cells, identifying novel IL-15 axis regulators that contribute to survival and persistence. Phenotypic screens similarly revealed regulators of NK cell cytotoxicity and interferon gamma production. By validating these targets, the team has demonstrated that they are able to regulate various aspects of NK and CAR-NK cell function.

πŸ‘οΈ0
jondoeuk jondoeuk 6 months ago
FT825/ONO-8250 update https://finance.yahoo.com/news/fate-therapeutics-announces-initiation-phase-130000499.html
πŸ‘οΈ0
Lilman72003 Lilman72003 6 months ago
Took my chips off the table and cashed out. $fate has worked in my favor I beat the street. In sub $2 out @ $4.50.

Thank you to the posters here I enjoyed the scientific discourse even if it was way over my head
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Looks like the inducement grant was for Dr. Cooley's replacement. Given the company's history, I was hoping that there would be a new CEO.
πŸ‘οΈ0
Lilman72003 Lilman72003 7 months ago
Took my profits, playing with house money riding freebies.
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Using CRISPR screening of metabolic genes, they found that KEAP1 played an important role in the pro-inflammatory activity of macrophages through inhibiting the production of itaconate. As ACOD1 is the sole enzyme to generate itaconate, ACOD1 knockout promoted pro-inflammatory activity of macrophages and enhanced the function of CAR-Ms derived from iPSCs https://www.nature.com/articles/s41467-023-41470-9
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Preprint https://www.biorxiv.org/content/10.1101/2023.12.10.570687v1
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Phase I Study of FT538 + Daratumumab for Treatment of r/r AML https://ash.confex.com/ash/2023/webprogram/Paper189132.html

FT538, iPSC-Derived NK Cells Are Potent Inducers of Apoptosis in AML Cells and Their Effect Is Synergistic in Combination with Approved Therapeutic Strategies https://ash.confex.com/ash/2023/webprogram/Paper187192.html

iPSC-derived natural killer cells expressing the FcyR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting https://jitc.bmj.com/content/11/12/e007280
πŸ‘οΈ0
jondoeuk jondoeuk 8 months ago
More preclinical data https://www.nature.com/articles/s41590-023-01687-8
πŸ‘οΈ0
jondoeuk jondoeuk 8 months ago
Enhancing cell therapy & regenerative medicine: advanced iPSC genome engineering via Logomix Genome-Writing platform https://jitc.bmj.com/content/11/Suppl_2/A1803
πŸ‘οΈ0
jondoeuk jondoeuk 8 months ago
New pipeline
πŸ‘οΈ0
jondoeuk jondoeuk 8 months ago
In that paper they were detectable for only 48 hours. NKs have an effective half-life of 1-2 weeks, memory-like longer, with early data (in H&N with anti-CTLA-4* and N-803) showing persistence out to at least 40 days.

* CTLA-4 blockade seems to impact phenotype with a skewing towards CD16+CD57+.
πŸ‘οΈ0
jondoeuk jondoeuk 8 months ago
Yes, that was one of at least five (from memory) trials testing aNKs (non-engineered NK-92s).

In metastatic pancreatic IBRX tested low-dose nab-paclitaxel, gemcitabine, aldoxorubicin, cyclophosphamide, low-dose SBRT, N-803 (an IL-15 superagonist) and PD-L1 CAR-NKs.

In all patients (3rd to 6th line) mOS is 5.8 months; median PFS 2.3 months. In 3rd line, mOS is 6.3 months. While this exceeds historical results, there were no controls.

Going forward (for other types), they plan on adding a number of other agents, including a heterologous prime-boost vaccine.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock